Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. In the first nine mont ...

However, the FDA also updated Trikafta's safety information, warning about potential risks of liver injury and failure. On another note, JPMorgan adjusted its price target for Vertex, lowering it ...

Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. In the first nine months of 2024, ...

However, the FDA also updated Trikafta's safety information, warning about potential risks of liver injury and failure. On another note, JPMorgan (NYSE:JPM) adjusted its price target for Vertex, ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...